Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost‐effectiveness study
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.13990
Abstract: Patients with metastatic gastrointestinal stromal tumours (GIST) are treated in first line with the oral tyrosine kinase inhibitor, imatinib, until progressive disease. With this fixed dosing regimen, only approximately 40% of patients reach adequate plasma… read more here.
Keywords: line; first line; gastrointestinal stromal; treated imatinib ... See more keywords
Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib
Sign Up to like & getrecommendations! Published in 2017 at "British Journal of Haematology"
DOI: 10.1111/bjh.14608
Abstract: Pulmonary hypertension (PH) is a rare, but life‐threatening, adverse event in patients treated with tyrosine kinase inhibitors (TKIs), such as dasatinib, but has not been fully evaluated in patients treated with imatinib or nilotinib. We… read more here.
Keywords: pulmonary hypertension; patients treated; imatinib nilotinib; treated imatinib ... See more keywords
Acute pancreatitis in a patient treated with imatinib and gefitinib
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/1078155220949639
Abstract: Introduction Use of oral antineoplastic agents (OAAs) has increased significantly in recent years. OAAs currently represent 30-50% of all cancer treatments. Drug interactions are the most frequent drug-related problem affecting OAAs. We describe the case… read more here.
Keywords: acute pancreatitis; gefitinib; treated imatinib; imatinib gefitinib ... See more keywords